Compare INBX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INBX | VALN |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 999.7M | 875.7M |
| IPO Year | 2024 | 2021 |
| Metric | INBX | VALN |
|---|---|---|
| Price | $61.49 | $6.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | N/A | ★ $15.75 |
| AVG Volume (30 Days) | ★ 155.9K | 86.6K |
| Earning Date | 03-19-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,300,000.00 | N/A |
| Revenue This Year | N/A | $4.00 |
| Revenue Next Year | N/A | $92.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 550.00 | N/A |
| 52 Week Low | $10.81 | $5.43 |
| 52 Week High | $94.57 | $12.25 |
| Indicator | INBX | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 37.65 | 25.15 |
| Support Level | $28.54 | $5.69 |
| Resistance Level | $85.97 | $6.73 |
| Average True Range (ATR) | 4.28 | 0.40 |
| MACD | -0.55 | -0.53 |
| Stochastic Oscillator | 21.52 | 0.84 |
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.